Literature DB >> 3394838

Increase in vagal activity during hypotensive lower-body negative pressure in humans.

K Sander-Jensen1, J Mehlsen, C Stadeager, N J Christensen, J Fahrenkrug, T W Schwartz, J Warberg, P Bie.   

Abstract

Progressive central hypovolemia is characterized by a normotensive, tachycardic stage followed by a reversible, hypotensive stage with slowing of the heart rate (HR). We investigated circulatory changes and arterial hormone concentrations in response to lower-body negative pressure (LBNP) in six volunteers before and after atropine administration. LBNP of 55 mmHg initially resulted in an increase in HR from 55 +/- 4 to 90 +/- 5 beats/min and decreases in mean arterial pressure (MAP) from 94 +/- 4 to 81 +/- 5 mmHg, in central venous pressure from 7 +/- 1 to -3 +/- 1 mmHg, and in cardiac output from 6.1 +/- 0.5 to 3.7 +/- 0.11/min. Concomitantly, epinephrine and norepinephrine levels increased. After 8.2 +/- 2.3 min of LBNP, the MAP had decreased to 41 +/- 7 mmHg and HR had decreased to 57 +/- 3 beats/min. Vasopressin increased from 1.2 +/- 0.3 to 137 +/- 45 pg/ml and renin activity increased from 1.45 +/- 4.0 to 3.80 +/- 1.0 ng.ml-1.h-1 with no further changes in epinephrine, norepinephrine, and vasoactive intestinal polypeptide. A tardy rise in pancreatic polypeptide indicated increased vagal activity. After atropine. LBNP also caused an initial increase in HR, which, however, remained elevated during the subsequent decrease in MAP to 45 +/- 6 mmHg occurring after 8.1 +/- 2.4 min.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3394838     DOI: 10.1152/ajpregu.1988.255.1.R149

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Validation of lower body negative pressure as an experimental model of hemorrhage.

Authors:  Carmen Hinojosa-Laborde; Robert E Shade; Gary W Muniz; Cassondra Bauer; Kathleen A Goei; Heather F Pidcoke; Kevin K Chung; Andrew P Cap; Victor A Convertino
Journal:  J Appl Physiol (1985)       Date:  2013-12-19

2.  Pharmacological manipulation of cardiovascular responses to lower body negative pressure.

Authors:  G Perko; J F Schmidt; J Warberg; N H Secher
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

3.  Classification of orthostatic intolerance through data analytics.

Authors:  Steven Gilmore; Joseph Hart; Justen Geddes; Christian H Olsen; Jesper Mehlsen; Pierre Gremaud; Mette S Olufsen
Journal:  Med Biol Eng Comput       Date:  2021-02-13       Impact factor: 2.602

Review 4.  A brief review of intradialytic hypotension with a focus on survival.

Authors:  Jason A Chou; Kamyar Kalantar-Zadeh; Anna T Mathew
Journal:  Semin Dial       Date:  2017-06-29       Impact factor: 3.455

5.  Phenylephrine increases near-infrared spectroscopy determined muscle oxygenation in men.

Authors:  H Sørensen; J H Thomsen; A S P Meyer; D Terzic; L Hilsted; J Kjærgaard; J P Goetze; T C Barbosa; N H Secher
Journal:  J Clin Monit Comput       Date:  2016-12-16       Impact factor: 2.502

6.  Effects of arginine-vasopressin on regional blood volume distribution in supine humans.

Authors:  H B Hopf; K D Stühmeier; W Klement; K J Langen; J Peters
Journal:  Basic Res Cardiol       Date:  1993 May-Jun       Impact factor: 17.165

7.  Early activation of the coagulation system during lower body negative pressure.

Authors:  M Zaar; P I Johansson; L B Nielsen; C G Crandall; M Shibasaki; L Hilsted; N H Secher
Journal:  Clin Physiol Funct Imaging       Date:  2009-07-28       Impact factor: 2.273

Review 8.  Mechanisms, Clinical Implications, and Treatment of Intradialytic Hypotension.

Authors:  Patrick B Reeves; Finnian R Mc Causland
Journal:  Clin J Am Soc Nephrol       Date:  2018-02-26       Impact factor: 8.237

9.  Transient receptor potential vanilloid 1 antagonist, capsazepine, improves survival in a rat hemorrhagic shock model.

Authors:  Hiroya Akabori; Hiroshi Yamamoto; Hiroshi Tsuchihashi; Tsuyoshi Mori; Kazunori Fujino; Tomoharu Shimizu; Yoshihiro Endo; Tohru Tani
Journal:  Ann Surg       Date:  2007-06       Impact factor: 12.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.